Colon to Rectum

Aliment Pharmacol Ther. 2022;56(6):932–41

Ingrosso MR, Ianiro G, Nee J, Lembo AJ, Moayyedi P, Black CJ, Ford AC

Systematic review and meta-analysis: Efficacy of peppermint oil in irritable bowel syndrome

Background: Irritable bowel syndrome (IBS) is one of the most common disorders of gut-brain interaction, with a complex pathophysiology. Antispasmodics are prescribed as first-line therapy because of their action on gut dysmotility. In this regard, peppermint oil also has antispasmodic properties.
Aim: To update their previous meta-analysis to assess efficacy and safety of peppermint oil, particularly as recent studies have cast doubt on its role in the treatment of IBS.
Methods: The authors searched the medical literature up to April 2, 2022 to identify randomized controlled trials (RCTs) of peppermint oil in IBS. Efficacy and safety were judged using dichotomous assessments of effect on global IBS symptoms or abdominal pain, and occurrence of any adverse event or of gastroesophageal reflux. Data were pooled using a random effects model, with efficacy and safety reported as pooled relative risks (RRs) with 95% confidence intervals (CIs).
Results: Ten eligible RCTs (1030 patients) were identified. Peppermint oil was more efficacious than placebo for global IBS symptoms (RR of not improving = 0.65, 95% CI: 0.43–0.98; number needed to treat [NNT] = 4, 95% CI: 2.5–71), and abdominal pain (RR of abdominal pain not improving = 0.76, 95% CI: 0.62–0.93; NNT = 7, 95% CI: 4–24). Adverse event rates were significantly higher with peppermint oil (RR of any adverse event = 1.57, 95% CI: 1.04–2.37).

Conclusions: Peppermint oil was superior to placebo for the treatment of irritable bowel syndrome (IBS), but adverse events were more frequent, and quality of evidence was very low. Adequately powered randomized controlled trials of peppermint oil as first-line treatment for IBS are needed.

Prof. Dr. A.C. Ford, Leeds Gastroenterology Institute, St. James’s University Hospital, Leeds, UK,

DOI: 10.1111/apt.17179

Back to overview

this could be of interest:

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from 3 phase 3, multicenter, double-blind, randomized trials

Lancet. 2022;399(10341):2113–28

Association of ultraprocessed food consumption with colorectal cancer risk among men and women: Results from 3 prospective US cohort studies

BMJ. 2022;378:e068921

More articles on the topic